Study probes hormone-linked gene expression in female dogs’ MCTs
Bottom line
A new study in Animals examined gene expression tied to hormone signaling and tumor growth in skin samples from intact and spayed female dogs, both with and without cutaneous mast cell tumors. The researchers evaluated markers including VEGF, IGF-1, PCNA, Ki-67, c-KIT, luteinizing hormone receptor, follicle-stimulating hormone receptor, and estrogen receptor alpha to explore whether reproductive status might shape the molecular environment around these tumors. The question matters because canine mast cell tumors are the most common malignant skin tumors in dogs, and prior work has suggested that gonadectomy may alter gonadotropin signaling in ways that could affect tumor biology. (mdpi.com)
Why it matters: For veterinary professionals, this study adds to a growing body of work looking beyond histologic grade alone and into whether endocrine status may influence mast cell tumor behavior. That doesn’t change clinical recommendations on spay timing or mast cell tumor management today, because broader reviews still describe the evidence on sex and neuter status as mixed or inconsistent. But it does reinforce that hormone receptor pathways, proliferation markers such as Ki-67, and angiogenesis-related signals like VEGF remain active areas of translational oncology research that could eventually inform risk stratification or targeted approaches. (mdpi.com)
What to watch: The next step is whether these gene-expression findings are validated in larger cohorts and linked to outcomes such as grade, recurrence, metastasis, or treatment response. (mdpi.com)
A new paper in Animals takes a closer look at whether reproductive status may influence the molecular profile of canine cutaneous mast cell tumors in female dogs. The study compared intact and spayed dogs, with and without mast cell tumors, and measured expression of hormone receptors and growth-related markers including luteinizing hormone receptor, follicle-stimulating hormone receptor, estrogen receptor alpha, VEGF, IGF-1, PCNA, Ki-67, and c-KIT. That focus puts endocrine biology back into a long-running veterinary oncology question: whether gonadectomy-related hormonal shifts could affect mast cell tumor development or behavior. (mdpi.com)
The backdrop is a disease veterinarians see often. Consensus and review papers describe canine mast cell tumors as among the most common skin neoplasms in dogs and the most common malignant skin tumor, with highly variable biologic behavior. Established prognostic tools still center on histologic grade, staging, mitotic activity, KIT abnormalities, and proliferation markers, but the etiology is not fully understood. Reviews also note that altered hormone-receptor expression has been proposed as one possible contributor, even though epidemiologic findings on sex and spay status remain inconsistent. (mdpi.com)
That’s where this study fits. According to the abstract, the authors set out to quantify gene expression in skin samples from four groups: healthy intact females, healthy spayed females, intact females with cutaneous mast cell tumors, and spayed females with cutaneous mast cell tumors. Their marker panel spans angiogenesis, proliferation, receptor tyrosine kinase signaling, and gonadotropin or estrogen responsiveness. Even without outcome data in the abstract, the design is notable because it compares both tumor-bearing and non-tumor-bearing tissue across reproductive statuses, which may help separate tumor-associated changes from broader endocrine effects of gonadectomy. (mdpi.com)
The paper also builds on earlier research rather than appearing in a vacuum. A 2022 Journal of the American Animal Hospital Association study reported increased luteinizing hormone receptor expression in neoplastic mast cells from spayed and neutered dogs, supporting the idea that gonadotropin signaling may be relevant in canine mast cell tumor biology. Broader desexing reviews have likewise noted reports of increased mast cell tumor risk in female dogs after gonadectomy, while emphasizing that the literature is heterogeneous and may vary by breed, sex, and study design. (pubmed.ncbi.nlm.nih.gov)
On the tumor-biology side, the markers chosen here are clinically familiar. Ki-67 and PCNA are associated with proliferation, c-KIT remains central to mast cell tumor pathogenesis and prognosis, and VEGF is tied to angiogenesis and has been evaluated in primary tumors and nodal metastases. That makes this study potentially useful as a bridge between endocrine hypotheses and the biomarker framework oncologists and pathologists already use in practice. Still, gene-expression work is an early step; expression differences don’t automatically translate into clinically actionable thresholds or treatment decisions. (mdpi.com)
Expert-facing commentary in the literature remains cautious. Recent clinical reviews for practitioners say mast cell tumors account for roughly 16% to 21% of canine cutaneous tumors, but also state that spay/neuter status does not appear to affect tumor development in a settled way. Meanwhile, oncology consensus reviews describe sex predisposition data as contradictory. Taken together, that suggests this new study is best viewed as mechanistic evidence that may explain some previously observed associations, not as proof that spay status independently drives clinical risk across the general dog population. (cliniciansbrief.com)
Why it matters: For veterinarians, the practical value is in sharpening biological understanding rather than changing case management today. If hormone receptor and growth-factor expression patterns are reproducibly different in spayed versus intact females with mast cell tumors, that could eventually matter for prognosis, biomarker interpretation, or even future targeted therapies. It may also inform how clinicians discuss the limits of current evidence with pet parents asking whether reproductive history contributed to a dog’s tumor. Right now, the safest takeaway is that mast cell tumor behavior remains multifactorial, and reproductive status is still an investigational variable rather than a standalone clinical rule. (mdpi.com)
What to watch: The key next step is full-text confirmation of which genes differed significantly, followed by larger prospective studies that connect those molecular findings to grade, recurrence, metastasis, survival, breed effects, and response to therapies such as surgery, vinblastine-based protocols, or tyrosine kinase inhibitors. (mdpi.com)